LeafNLP Demos
Back to explore

Report #2870591

Received Nov 4, 2025

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
74 yrs
State
NC
Recovered
Not recovered
Vaccinated
Jul 9, 2025
Onset
Jul 16, 2025
Days to onset
7
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (AREXVY)GLAXOSMITHKLINE BIOLOGICALSUNKEH25MIM

Symptoms (1)

Injection site pain

Symptom narrative

Pain injection site; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 74-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number EH25M, expiry date 29-OCT-2025) for prophylaxis. On 09-JUL-2025, the patient received Arexvy (intramuscular, unknown deltoid). On 16-JUL-2025, 7 days after receiving Arexvy, the patient experienced injection site pain (Verbatim: Pain injection site). The outcome of the injection site pain was not resolved. It was unknown if the reporter considered the injection site pain to be related to Arexvy. It was unknown if the company considered the injection site pain to be related to Arexvy. Additional Information: GSK receipt date:16-OCT-2025 The pharmacist reported that a patient received her Arexvy vaccination on 9th July 2025 and about one week later she noted pain about 1 inch below the injection site. The pain continued intermittently.